Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1990-10-11
|
| pubmed:abstractText |
Immunohistochemical and immunophenotypic analyses were performed on 278 cases of karyotypically abnormal non-Hodgkin's lymphoma (NHL). Excluding cases of lymphoblastic lymphoma or mycosis fungoides, 20 cases showed evidence of non-B cell lineage. T cell lineage was proven by genotypic and immunophenotypic analyses in 15 of the 20 cases; five were of ambiguous lineage. All of the non-B lineage cases were of diffuse histology with a large cell component (DLCL). Twelve cases expressed the Ki-1 antigen; five of these cases also demonstrated a translocation with a break at 5q35. Patients with Ki-1 positive DLCL and t(5q35) had a younger median age compared with non-B cell DLCL without t(5q35). The Ki-1 positive patients had a higher frequency of skin involvement and lower incidence of bone marrow involvement compared with Ki-1 negative DLCL. Survival analysis was performed on 86 cases of B cell DLCL and 18 cases of non-B cell DLCL which were serially ascertained prior to receiving cytotoxic chemotherapy. Median duration of complete remission was significantly longer in the B cell compared with the non-B cell DLCL groups; there was only a trend for decreased overall survival in the non-B cell group. Among the subset of non-B cell lymphomas, overall survival of patients with Ki-1 expressing DLCL was significantly longer than those with Ki-1 negative DLCL, who had a median survival of less than a year. These results show that immunophenotypic, immunohistochemical, and cytogenetic markers can define subsets of patients with non-B cell lymphomas with differing clinical characteristics and outcome.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
625-30
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:2168505-Adolescent,
pubmed-meshheading:2168505-Adult,
pubmed-meshheading:2168505-Aged,
pubmed-meshheading:2168505-Antigens, CD,
pubmed-meshheading:2168505-Antigens, CD30,
pubmed-meshheading:2168505-Antigens, Differentiation,
pubmed-meshheading:2168505-Antigens, Neoplasm,
pubmed-meshheading:2168505-Child,
pubmed-meshheading:2168505-Chromosomes, Human, Pair 2,
pubmed-meshheading:2168505-Chromosomes, Human, Pair 5,
pubmed-meshheading:2168505-Female,
pubmed-meshheading:2168505-Humans,
pubmed-meshheading:2168505-Immunohistochemistry,
pubmed-meshheading:2168505-Lymphoma, Non-Hodgkin,
pubmed-meshheading:2168505-Male,
pubmed-meshheading:2168505-Middle Aged,
pubmed-meshheading:2168505-Phenotype,
pubmed-meshheading:2168505-Prognosis,
pubmed-meshheading:2168505-T-Lymphocytes,
pubmed-meshheading:2168505-Translocation, Genetic
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Ki-1 antigen expression defines a favorable clinical subset of non-B cell non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Department of Pathology, Memorial Hospital, New York, New York.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|